Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alli first centralized switch

This article was originally published in The Tan Sheet

Executive Summary

The European Union approves GlaxoSmithKline's weight-loss drug alli (orlistat 60 mg) for nonprescription sale in all 27 member states and Norway. The company says Jan. 21 it plans to launch alli - the first centralized EU switch - in the coming months. While all EU members agree to sell alli as nonprescription, each country chooses whether to make it available over the counter or behind the counter, the European Medicines Agency says (1"The Tan Sheet" Nov. 17, 2008, p. 6)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts